LearnGlossaryMarketStocksSuperinvestorsSign in

NVCR

Novocure Ltd

Healthcare · $1.9B market cap

Verdict

We can't put a fair value on NVCR right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth10.4% a year✓
Sales growth18.8% a year✓
Free cash flow growth—?
Return on invested capital-22.1%✗

Follow NVCR

Track it on your watchlist and see the full analysis. Free.

Create a free account

About Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works